Immunic News

Express News | Immunic Announces Publication of Extended Data From Phase 2 Emphasis Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunology & Neuroinflammation

ReutersApr 30 06:30 ET

Immunic CEO Dr Daniel Vitt Marks International Day of Immunology With Discussion on Its Crucial Role

Yahoo FinanceApr 29 11:11 ET

Analysts Offer Insights on Healthcare Companies: Adaptimmune Therapeutics (ADAP) and Immunic (IMUX)

TipRanksApr 16 02:50 ET

Top 10 Stocks With Upwards and Downwards Daily Percentage Change - Piper Sandler

Seeking AlphaApr 12 11:34 ET

Analysts Offer Insights on Healthcare Companies: Immunic (IMUX), DocGo (DCGO) and Alkermes (ALKS)

TipRanksApr 10 07:20 ET

Brookline Capital Starts Immunic at Buy, Cites MS Drug Candidate

Seeking AlphaApr 5 13:00 ET

Express News | Immunic Shares Are Trading Higher After Brookline Capital Initiated Coverage on the Stock With a Buy Rating and a Price Target of $10

Moomoo 24/7Apr 5 07:27 ET

Brookline Analyst Bullish on Immunic Stock on MS Potential

InvestingApr 5 05:20 ET

Immunic Initiated at Buy by Brookline Capital

Immunic Initiated at Buy by Brookline Capital

Dow JonesApr 5 05:09 ET

Express News | Brookline Capital Initiates Coverage On Immunic With Buy Rating, Announces Price Target of $10

Moomoo 24/7Apr 5 04:59 ET

Immunic Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/05/2024 693.65% Brookline Capital → $10 Initiates Coverage On → Buy 10/10/2023 455.56% Wedbush $5 → $7

BenzingaApr 5 04:57 ET

Analysts Offer Insights on Healthcare Companies: Immunic (IMUX) and Shockwave Medical (SWAV)

TipRanksApr 5 04:50 ET

AbbVie Acquisition Signals Confidence in Small-cap Biotech Sector's Growth Potential | NASDAQ:IMUX

Proactive InvestorsMar 26 10:47 ET

Immunic Gets US Patent Notice of Allowance For Specific Polymorph of Vidofludimus Calcium

Immunic (IMUX) said Wednesday it has received a notice of allowance from the US Patent and Trademark Office covering a specific polymorph of vidofludimus calcium, its lead drug candidate. The firm sai

MT NewswiresMar 21 12:56 ET

Immunic CMO Discusses Complexities of Multiple Sclerosis to Mark MS Awareness Month

Yahoo FinanceMar 21 12:14 ET

Immunic Secures Key Patent, Boosting MS Drug Exclusivity and Global IP Strategy

Yahoo FinanceMar 21 11:37 ET

Express News | Immunic Has Received A Notice Of Allowance From United States Patent And Trademark Office For Patent Covering Composition-Of-Matter Of Vidofludimus Calcium (IMU-838) And Related Production Method, Expected To Provide Protection Into 2039

Moomoo 24/7Mar 20 06:33 ET

Immunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United States

– Patent Will Also Cover a Related Method of Production of the Material – – Fourth U.S. Patent Directed to Use of Vidofludimus Calcium in Multiple Sclerosis – – Multilayered Intellectual Property Str

PR NewswireMar 20 06:30 ET

Immunic to Reveal Promising MS Treatment Data in Two Poster Presentations at ACTRIMS Forum 2024

Yahoo FinanceMar 8 06:53 ET

Immunic to Participate in Investor and Scientific Conferences in March

Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic...

PR NewswireMar 7 06:30 ET